News & Publications

Chief Scientific Officer of Gate Neurosciences, Anantha Shekhar, MD, PhD, discusses Gate Neuroscience's phase 1 study of rapid-acting antidepressant, apimostinel, with Psychiatric Times.

Gate Neurosciences was featured in Psychiatric Times’ mental health minute video series. Co-founder of Gate Neurosciences and Senior Vice Chancellor for Health Sciences and Dean of the University of Pittsburgh School of Medicine, Dr. Shekhar, discusses apimostinel, a safe and rapid-acting injectable being developed for acute depression, and Gate Neuro’s ongoing EEG biomarker study.

Gate Neurosciences Doses First Subject in a Translational EEG Biomarker Study of Apimostinel, a Rapid-Acting Treatment for Acute Depressive Disorders

Gate Neurosciences today announced that the first cohort of subjects has been dosed in its Phase 1 biomarker and multiple ascending dose study of apimostinel, the company’s 2nd generation rapid-acting injectable NMDAR modulator program.

Gate Neurosciences Publishes Data Highlighting Novel Mechanism of Lead Rapid-Acting Oral Antidepressant and Provides Business Update

Gate Neurosciences today announced the results of research, published in the International Journal of Neuropsychopharmacology, supporting the mechanism of action and clinical foundation of Zelquistinel – the company’s lead oral program in Phase 2 development – as a rapid-acting, long-lasting and safe antidepressant.

Gate Neurosciences Emerges from Stealth with a Portfolio of Next-Generation Therapies for Central Nervous System Diseases

Gate Neurosciences today announced it has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders.

Zelquistinel is an Orally Bioavailable Novel NMDAR Modulator that Exhibits Rapid & Sustained Antidepressant Effects

Highlights our lead program, Zelquistinel, and it’s unique mechanism of positive NMDA receptor modulation and that enhances long-term potentiation and synaptic function, resulting in rapid and sustained antidepressant activity with an improved safety profile versus NMDA antagonists.

Repeated Administration of Rapastinel Produces Prolonged Rescue of Memory Deficits in Mice Treated with NMDAR Antagonists

Highlights the differentiated mechanism and effects on cognition of our class of NMDAR modulators, compared to NMDAR antagonists. Gate’s unique NMDAR modulator mechanism reverses and rescues brain deficits caused by NMDAR antagonists such as PCP and ketamine.

Positive Modulation of NMDA Receptors by AGN-241751 exerts rapid antidepressant effects via Excitatory Neurons

Highlights our lead program, Zelquistinel, and the novel NMDAR mechanism by which our compounds act on excitatory neurons in the mPFC, but not inhibitory neurons, to drive antidepressant effects

Cell-Type Specific Modulation of NMDA Receptors Triggers Antidepressant Actions

Highlights and differentiates the mechanistic pathways by which Gate’s NMDAR positive modulators, and NMDA antagonists (ie ketamine), can both exert rapid antidepressant effects. Gate’s NMDA modulators directly enhance receptor function on principal glutamatergic neurons in the mPFC, whereas antagonists block NMDA on GABA interneurons causing a glutamate efflux (and dissociative side effects) and indirect activation of excitatory synapse.

Rapastinel Alleviates the Neurotoxic Effects Induced by NMDA Receptor Blockade

Highlights data showing that Gate’s NMDAR modulators protect against the neurotoxic effects of NMDAR antagonists, especially in early neurodevelopment.

NMDAR Modulators as Rapid Antidepressants, Converging and Distinct Signaling Mechanisms

Highlights data showing that Gate’s NMDAR modulators protect against the neurotoxic effects of NMDAR antagonists, especially in early neurodevelopment.

1 2